⚠ Evidence note: Mechanistic aging biology translates to human interventions slowly and unreliably; model-organism lifespan gains have repeatedly failed to transfer.
NAMPT and NAD Biosynthesis in Aging
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-11-01 — A Cilia-Centered Nicotinamide Adenine Dinucleotide (NAD) Signaling Network Regulates Hypothalamic Lysosomal Homeostasis and Metabolic Aging.: cross-connection with autophagy: [animal-model] The reported hypothalamic NAD+–primary-cilia–CHMP4B pathway connects NAD availability to lysosomal repair; it does not establish NAMPT as the causal regulator or show that NAD-precursor supplementation restores this pathway in humans. (novelty: 3)
- 2026-10-10 — THE AGING PURINOME: A PURINERGIC FRAMEWORK LINKING THE HALLMARKS OF AGING TO INFLAMMAGING.: cross-connection with aging-purinome: The Aging Purinome framework explicitly fuses extracellular purinergic signaling with NAD+ biosynthetic metabolism, formally bridging the ATP/adenosine receptor literature to the NAMPT/NAD axis as a shared nucleotide-economy substrate of aging. (novelty: 3)
- 2026-10-02 — Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults: cross-connection with vascular-aging: NR confirmatory RCT links NAD+ precursor supplementation (NAMPT-adjacent salvage pathway substrate) to a human vascular-aging endpoint (SBP, arterial stiffness) for the first time at adequate power. (novelty: 3)
- 2026-07-28 — Enhancing the anti-ageing capacity of hUC-MSCs via NMN co-treatment in D-galactose-induced ageing mice and cellular senescence models.: cross-connection with stem-cell-exhaustion: NMN pretreatment of hUC-MSCs reduces post-transplant stem-cell senescence and improves anti-aging efficacy in D-galactose mice, linking NAD-precursor availability to the longevity of exogenous MSC grafts. (novelty: 3)
- 2025-11-22 — Nicotinamide riboside supplementation restores microglial health and improves cognition in aged male mice.: cross-connection with inflammaging: NR-driven NAD precursor supply shifts aged microglia away from inflammatory ADEM/DAM states toward homeostatic phenotypes in aged mice, operationalizing a specific NAD-biosynthesis→CNS-inflammaging link via brain-resident macrophages. (novelty: 3)
- 2026-07-21 — β-Nicotinamide mononucleotide reduces aflatoxin B1 induced liver injury via the gut microbiota-bile acid-farnesoid X receptor (FXR/NR1H4) axis.: cross-connection with gut-microbiota-bile-acid-fxr-fgf15-muscle: NMN, an NAD+ precursor normally framed through NAMPT/NAD biosynthesis, here acts hepatoprotectively via the gut microbiota–bile acid–intestinal FXR/FGF15 axis, suggesting NAD-precursor effects may partly route through microbiota–bile-acid signaling rather than cell-autonomous NAD repletion alone. (novelty: 3)
- 2026-05-25 — A sustained NADsupplementation-biosynthesis nanoplatform for metabolic restoration in aged bone regeneration.: cross-connection with cellular-senescence: Combining exogenous NAD precursor supply with support for endogenous NAD biosynthesis (NAMPT-axis) in a single local-release platform reduces senescent BMSC fraction, operationally linking the NAMPT/NAD-biosynthesis page to senescent-cell rescue in a bone niche. (novelty: 3)
- 2026-08-29 — NADprecursor treatment prevents cardiomyopathy but disrupts erythroid maturation in mitochondrial progeria.: cross-connection with reductive-stress: Chronic NR in mutator mice pushed bone marrow into reductive stress, providing an in vivo mammalian example that NAD-precursor loading can tip the NAD(P)H/GSH balance toward reductive stress rather than restore oxidative flux. (novelty: 3)
- 2026-09-16 — Endothelial C/EBPβ/AEP pathway drives vascular deterioration and systemic aging.: 2026 mouse study: endothelial C/EBPβ drives AEP (legumain) expression, which proteolytically cleaves NAMPT to deplete systemic NAD; AEP-resistant NAMPT (N136A knock-in) or AEP ablation restores NAD, rescues vascular integrity, and extends lifespan in Tie2-C/EBPβ mice, with AEP inhibitor CP#11A outperforming NMN — nominates NAMPT proteolysis (not just expression decline) as an upstream, druggable node of age-related NAD loss. [animal-model] (novelty: 4)
Open questions
Related
Contributing findings
Endothelial C/EBPβ/AEP pathway drives vascular deterioration and systemic aging.
16-sep-2026
novelty 4
per-area 4
strengthens